A trend in the last few years has been the addition of the sliding barn door as an alternative to a traditional swing or pocket door inside the home. Often these doors are a focal point and designed to be admired for their beauty and uniqueness — if not for their functionality. Here at Dreambuilder…Read more
WASHINGTON (AP) – Aug. 15, 2014 – Average long-term U.S. mortgage rates declined this week, approaching their lows for the year. Mortgage company Freddie Mac said Thursday the nationwide average for a 30-year loan slipped to 4.12 percent from 4.14 percent last week. The average for a 15-year mortgage, a popular choice for people who…Read more
Dreambuilder Custom Homes is proud to announce the completion of Dreambuilder 17, our oceanfront home in Jacksonville Beach built for the Kane family.
Matt and Alexis Kane first met with Dreambuilder regarding building in the Avondale area of Jacksonville, but due to its proximity to their workplaces the lot search turned to the beach. Dreambuilder brought in Realtor Sherri Beno to assist with the search, and soon enough the lot at 2701 Ocean Drive was under contact.Read more
As you may know, Dreambuilder Custom Homes has been supporting the Cystic Fibrosis Foundation for many years in its search for a cure for this devastating illness. Great strides are being made in research and treatments! Read below for the latest news:
We are writing with exciting news. Tuesday morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
The studies showed that, compared with those on placebo, participants who took the combination treatment showed significant and consistent improvement in lung function and in other important health measures, including weight gain, and a reduction in the rate of pulmonary exacerbations.
Click below to read our web story, which includes the Vertex press release: click here
These positive results represent an important milestone in the history of CF – and a significant step forward in our effort to bring new treatments targeting the underlying cause of the disease to all people with CF.
Based on these results, Vertex plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) by the end of this year. While we cannot predict the outcome of the FDA’s review, we believe the Phase 3 results present a compelling case for the approval of this much-needed potential new treatment.Read more
by Martin Crutsinger, Associated Press WASHINGTON (AP) – July 3, 2014 – Average U.S. mortgage rates are near historically low levels. Mortgage company Freddie Mac said Thursday that the nationwide average rate for a 30-year loan dipped to 4.12 percent, down from 4.14 last week. The average for the 15-year mortgage, which had taken a…Read more